IL320024A - מעכב perk hc-5404 בשילוב עם נוגדן אנטי-pd-1 ו/או חומר אנטי אנגיוגנטי לשימוש בטיפול בסרטן - Google Patents
מעכב perk hc-5404 בשילוב עם נוגדן אנטי-pd-1 ו/או חומר אנטי אנגיוגנטי לשימוש בטיפול בסרטןInfo
- Publication number
- IL320024A IL320024A IL320024A IL32002425A IL320024A IL 320024 A IL320024 A IL 320024A IL 320024 A IL320024 A IL 320024A IL 32002425 A IL32002425 A IL 32002425A IL 320024 A IL320024 A IL 320024A
- Authority
- IL
- Israel
- Prior art keywords
- effective amount
- antibody
- therapeutically effective
- combination
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263413116P | 2022-10-04 | 2022-10-04 | |
| US202363443344P | 2023-02-03 | 2023-02-03 | |
| US202363455911P | 2023-03-30 | 2023-03-30 | |
| PCT/US2023/076006 WO2024077099A1 (en) | 2022-10-04 | 2023-10-04 | Perk inhibitor hc-5404 in combination with anti-pd-1 antibody and/or an antiangiogenetic agent for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320024A true IL320024A (he) | 2025-06-01 |
Family
ID=88690304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320024A IL320024A (he) | 2022-10-04 | 2023-10-04 | מעכב perk hc-5404 בשילוב עם נוגדן אנטי-pd-1 ו/או חומר אנטי אנגיוגנטי לשימוש בטיפול בסרטן |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4598523A1 (he) |
| JP (1) | JP2025533802A (he) |
| KR (1) | KR20250078561A (he) |
| CN (1) | CN120787153A (he) |
| AU (1) | AU2023356307A1 (he) |
| CA (1) | CA3269342A1 (he) |
| IL (1) | IL320024A (he) |
| MX (1) | MX2025004037A (he) |
| WO (1) | WO2024077099A1 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121399099A (zh) * | 2023-03-30 | 2026-01-23 | 希伯塞尔股份有限公司 | (r)-2-氨基-5-(4-(2-(3,5-二氟苯基)-2-羟基乙酰胺基)-2-甲基苯基)-n-异丙基烟酰胺的晶形及其使用方法 |
| WO2025137710A1 (en) * | 2023-12-22 | 2025-06-26 | Hibercell, Inc. | Methods of treating cancer using combinations of gcn2 modulators and belzutifan |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095156A1 (en) * | 2018-03-26 | 2019-10-03 | Icahn School Of Medicine At Mount Sinai | Methods of treating minimal residual cancer |
| WO2020142694A2 (en) * | 2019-01-03 | 2020-07-09 | Musc Foundation For Research Development | Ero1-alpha inhibitors |
| CN112807434B (zh) * | 2020-12-30 | 2022-04-05 | 中山大学 | Perk抑制剂在制备肝癌药物的增效剂中的应用 |
-
2023
- 2023-10-04 WO PCT/US2023/076006 patent/WO2024077099A1/en not_active Ceased
- 2023-10-04 JP JP2025518841A patent/JP2025533802A/ja active Pending
- 2023-10-04 CA CA3269342A patent/CA3269342A1/en active Pending
- 2023-10-04 EP EP23800705.8A patent/EP4598523A1/en active Pending
- 2023-10-04 KR KR1020257014637A patent/KR20250078561A/ko active Pending
- 2023-10-04 AU AU2023356307A patent/AU2023356307A1/en active Pending
- 2023-10-04 CN CN202380083469.3A patent/CN120787153A/zh active Pending
- 2023-10-04 IL IL320024A patent/IL320024A/he unknown
-
2025
- 2025-04-03 MX MX2025004037A patent/MX2025004037A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025533802A (ja) | 2025-10-09 |
| WO2024077099A1 (en) | 2024-04-11 |
| CA3269342A1 (en) | 2024-04-11 |
| KR20250078561A (ko) | 2025-06-02 |
| AU2023356307A1 (en) | 2025-04-10 |
| CN120787153A (zh) | 2025-10-14 |
| EP4598523A1 (en) | 2025-08-13 |
| MX2025004037A (es) | 2025-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273188B (he) | טיפול בשילוב של מעכבי קולטן כימוקין 2 (ccr2) ומעכב pd-1/pd-l1 | |
| IL320024A (he) | מעכב perk hc-5404 בשילוב עם נוגדן אנטי-pd-1 ו/או חומר אנטי אנגיוגנטי לשימוש בטיפול בסרטן | |
| JOP20220163A1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| IL300151A (he) | צירופים לטיפול בסרטן | |
| EP4643882A3 (en) | Capsid inhibitors for the prevention of hiv | |
| JOP20230118A1 (ar) | مركب كربوكساميد أريل غير متجانس | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| EP4353747A3 (en) | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| JP2019533715A5 (he) | ||
| RU2020109376A (ru) | Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| JP2016537380A5 (he) | ||
| EE200200565A (et) | Vaskulaarse kahjustava toimega kombinatsioonravi | |
| PE20221768A1 (es) | Inhibidores de egfr | |
| WO2019136157A3 (en) | Reducing beta-catenin and ido expression to potentiate immunotherapy | |
| WO2023240082A3 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| FI3646869T3 (fi) | Solunsalpaajahoito atsabisykloyhdisteellä syövän hoitamiseksi | |
| MX2021006210A (es) | Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica. | |
| JP2022513029A5 (he) | ||
| JOP20210221A1 (ar) | علاجات مشتركة لاستخدامها في علاج السرطان |